Citadel Advisors - ASCENDIS PHARMA A/S ownership

ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of ASCENDIS PHARMA A/S
ValueSharesWeighting
Q3 2023$3,113,343
-63.8%
33,248
-65.5%
0.00%
-100.0%
Q2 2023$8,610,126
-56.3%
96,472
-47.5%
0.00%
-75.0%
Q1 2023$19,717,973
-57.2%
183,902
-51.2%
0.00%
-63.6%
Q4 2022$46,016,874
+97.4%
376,786
+66.9%
0.01%
+120.0%
Q3 2022$23,310,000
+70.6%
225,740
+53.6%
0.01%
+66.7%
Q2 2022$13,664,000
-32.2%
146,988
-14.4%
0.00%
-25.0%
Q1 2022$20,163,000
+94.8%
171,800
+123.3%
0.00%
+300.0%
Q4 2021$10,349,000
-4.8%
76,926
+12.8%
0.00%
-50.0%
Q3 2021$10,867,000
-73.8%
68,178
-78.4%
0.00%
-77.8%
Q2 2021$41,474,000
+133.7%
315,275
+128.9%
0.01%
+125.0%
Q1 2021$17,748,000
-68.4%
137,715
-59.1%
0.00%
-71.4%
Q4 2020$56,207,000
-29.3%
337,014
-34.6%
0.01%
-39.1%
Q3 2020$79,504,000
+7.8%
515,187
+3.3%
0.02%
-11.5%
Q2 2020$73,735,000
+141.4%
498,543
+83.8%
0.03%
+100.0%
Q1 2020$30,540,000
-49.8%
271,200
-38.0%
0.01%
-50.0%
Q4 2019$60,863,000
+758.4%
437,482
+494.3%
0.03%
+766.7%
Q3 2019$7,090,000
-77.0%
73,612
-72.5%
0.00%
-78.6%
Q2 2019$30,834,000
-65.2%
267,768
-64.4%
0.01%
-68.9%
Q1 2019$88,637,000
+1106.9%
753,076
+542.5%
0.04%
+1025.0%
Q4 2018$7,344,000
+240.3%
117,209
+284.9%
0.00%
Q3 2018$2,158,000
-13.4%
30,449
-18.8%
0.00%
-100.0%
Q2 2018$2,493,000
+570.2%
37,478
+264.8%
0.00%
Q3 2017$372,000
+1671.4%
10,273
+788.7%
0.00%
Q4 2015$21,000
-67.7%
1,156
-68.6%
0.00%
Q3 2015$65,000
-93.8%
3,687
-93.9%
0.00%
-100.0%
Q1 2015$1,046,00060,3160.00%
Other shareholders
ASCENDIS PHARMA A/S shareholders Q1 2022
NameSharesValueWeighting ↓
RA Capital Management 11,225,357$1,001,863,11218.92%
Q Global Advisors, LLC 195,000$17,40412.55%
Sofinnova Investments, Inc. 754,032$67,297,3564.41%
Avoro Capital Advisors LLC 3,580,555$319,564,5344.34%
Finepoint Capital LP 139,772$12,474,6514.32%
Spyglass Capital Management LLC 657,853$58,713,3804.24%
Saturn V Capital Management LP 78,442$7,000,9483.88%
DAFNA Capital Management LLC 135,212$12,067,6713.30%
ARS Investment Partners, LLC 289,860$25,870,0053.02%
Ghost Tree Capital, LLC 100,000$8,925,0002.95%
View complete list of ASCENDIS PHARMA A/S shareholders